Analyzing Guardant Health’s Unusual Options Activity
Guardant Health (NASDAQ:GH) shares experienced unusual options activity on Thursday. The stock price moved up to $114.16 following the option alert.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
TwinStrand Biosciences Reports Filed Patent Infringement Suit Against Guardant Health
TwinStrand Biosciences, Inc. announced today that it filed a patent infringement lawsuit against Guardant Health, Inc. (NASDAQ:GH). TwinStrand and its exclusive licensor, the University of Washington, filed the lawsuit
Lunit Reports $26M Strategic Investment From Guardant Health, No Terms Disclosed
Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company.
The deal, which includes
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
Guardant Health Insights: Return On Capital Employed
During Q1, Guardant Health's (NASDAQ:GH) reported sales totaled $78.67 million. Despite a 18.31% in earnings, the company posted a loss of $107.86 million. Guardant Health collected $78.32 million in revenue during Q4, but reported earnings showed a $91.17 million loss.
Wells Fargo Maintains Overweight on Guardant Health, Raises Price Target to $160
Wells Fargo analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $145 to $160.
Raymond James Initiates Coverage On Guardant Health with Market Perform Rating
Raymond James analyst Andrew Cooper initiates coverage on Guardant Health (NASDAQ:GH) with a Market Perform rating.